Method of reducing multi-drug resistance using inositol tripyrophosphate
AssigneesNormOxys, Inc., Universite De Strasbourg
InventorsYves Claude Nicolau, Jean-Marie Lehn, Claudine Kieda
Life of this patent
Estimating the term…
Abstract
Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.
Claims35
A method for treating cancer, comprising
- administering to a subject in need thereof a therapeutically effective amount of ITPP;
- and
- administering to the subject a therapeutically effective amount of a chemotherapeutic agent following the partial vascular normalization in the tumor.
The method of claim 3, wherein the occurrence of partial vascular normalization is detected by measuring partial oxygen pressure (pO2) level of the tumor.
A pharmaceutical composition comprising inositol trispyrophosphate (ITPP) and a chemotherapeutic agent selected from paclitaxel and cisplatin.
A treatment regimen for treating cancer in a subject, comprising administering simultaneously or sequentially a therapeutically effective amount of ITPP and a chemotherapeutic agent selected from paclitaxel and cisplatin.
A pharmaceutical composition comprising inositol trispyrophosphate (ITPP) and a sub-therapeutic amount of a chemotherapeutic agent.
A treatment regimen for treating cancer in a subject, comprising administering simultaneously or sequentially a therapeutically effective amount of ITPP and a sub-therapeutic amount of a chemotherapeutic agent.
A method for treating cancer in a subject, comprising administering simultaneously or sequentially a therapeutically effective amount of ITPP and a sub-therapeutic amount of a chemotherapeutic agent.
A method for treating a multi-drug resistant cancer in a subject, comprising administering a therapeutically effective amount of ITPP.
A method for treating a hyper-proliferative condition comprising administering to a subject in need thereof a therapeutically effective amount of ITPP, wherein the hyper-proliferative condition is not cancer or characterized by undesired angiogenesis.
A method for enhancing immune response in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of ITPP, wherein the subject does not suffer from cancer or another tumor.
Dependencies are inferred from the claim text.